IFNG and cancer: Given the non‐negligible presence of the IFN‐γ dominant subtype in cancers with higher rates of HPD, future studies are needed to characterize how the immune landscape of each tumor type contributes to differential responses to immunotherapy, as well as how it is altered by the introduction of immunotherapeutic agents in the TME.